Palvella Therapeutics, Inc. (PVLA)

Palvella Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Selling, General & Admin	4.84	3.08	4.16
Research & Development	6.31	8.79	13.88
Operating Expenses	11.15	11.87	18.04
Operating Income	-11.15	-11.87	-18.04
Interest Expense	-4.16	-	-10.36
Interest & Investment Income	-	6.27	-
Other Non Operating Income (Expenses)	-0.74	1.2	-0.17
EBT Excluding Unusual Items	-16.04	-4.41	-28.58
Other Unusual Items	23.1	23.1	-
Pretax Income	7.06	18.69	-28.58
Income Tax Expense	-	-	-1.03
Net Income	7.06	18.69	-27.55
Preferred Dividends & Other Adjustments	14.81	14.81	-
Net Income to Common	-7.75	3.88	-27.55
Shares Outstanding (Basic)	6	6	6
Shares Outstanding (Diluted)	6	6	6
Shares Change (YoY)	0.02%	1.36%	-
EPS (Basic)	-1.36	0.68	-4.82
EPS (Diluted)	-1.36	0.67	-4.82
EBIT	-11.15	-11.87	-18.04

Updated Dec 16, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q